Partnerships | Isomorphic Labs

Isomorphic Labs' partnerships page describes its collaboration with Novartis, announced in January 2024 and expanded in February 2025, initially targeting small-molecule therapeutics against three challenging targets and later expanding to up to three additional research programs. Fiona Marshall, President of Biomedical Research at Novartis, is quoted: "Over the past year, we have witnessed the exploration of new chemical spaces that would be unavailable to probe through traditional methods." The page gives no further numeric outcomes beyond the target/program counts and dates.

Google supplies AI to pharma through several distinct lines — Gemini/Vertex AI as an enterprise platform, and AlphaFold-based drug design licensed commercially through Isomorphic Labs.

This sits in the Build stage of the AI use-case lifecycle: Named examples from the foundation-model labs and platforms pharma teams use to actually construct, train and generate the model or application.